Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 51, Issue 5, 2006, Pages 968-975

  Czaja, Albert J ^a   Carpenter, Herschel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Azathioprine; Thiopurine methyltransferase; Treatment

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOPENIA; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AZATHIOPRINE; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745831588     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9336-5     Document Type: Article

References (48)

1. Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479-497, 2002
2. Czaja AJ: Treatment of autoimmune hepatitis. Semin Liver Dis 22:365-377, 2002
3. Bacon BR, Treuhaft WH, Goodman AM: Azathioprine-induced pancytopenia. Occurrence in two patients with connective tissue diseases. Arch Intern Med 141:223-226, 1981
4. Hohlfeld R, Michels M, Heininger K, Besinger V, Toyka KV: Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38:258-261, 1988
5. Jeurissen MEC, Boerbooms AMTH, Van De Putte LBA: Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 47:503-505, 1988
6. Maddocks JL, Lennard L, Amess J, Amor R, Meyrick Thomas R: Azathioprine and severe bone marrow depression. Lancet i:156, 1986
7. Ben Ari Z, Mehta A, Lennard L, Burroughs AK: Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 23:351-354, 1995
8. Czaja AJ, Wolf AM, Baggenstoss AH: Clinical assessment of cirrhosis in severe chronic active liver disease (CALD): Specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc 55:360-364, 1980
9. Czaja AJ: Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6:799-824, 2002
10. Johnson PJ, McFarlane IG, Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333:958-963, 1995
11. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG: Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 37:441-447, 2002
12. Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904-915, 2002
13. Cuffari C, Dassopoulis T, Turnbough L, Thompson RE, Bayless TM: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2:410-117, 2004
14. Black AJ, McLeod HL, Capell HA, et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716-718, 1998
15. Lennard L, Welch JC, Lilleyman JS: Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 44:455-161, 1997
16. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567-572, 2000
17. Lichtenstein GR: Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy. Gastroenterology 127:1558-1564, 2004
18. Regueiro M, Mardini H: Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 35:240-244, 2002
19. Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817-2823, 1999
20. Heneghan MA, McFarlane IG: Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35:7-13, 2002
21. Bertino JR: Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man. Arthritis Rheum 16:79-83, 1973
22. Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329-39, 1992
23. Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM: Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 30:358-363, 1990
24. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M: Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 26:220-226, 2004
25. Szumlanski C, Honchel R, Scott M, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics 2:148-159, 1992
26. Krynetski EY, Tai HL, Yates CR, et al.: Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6:279-290, 1996
27. Otterness D, Szumlanski C, Lennard L, et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62:60-73, 1997
28. Yates CR, Krynetski EY, Loennechen T, et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614, 1997
29. Alves S, Prata MJ, Ferreira F, Amorim A: Screening of thiopurine methyl s-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat 15:246-253, 2000
30. McLeod HL, Lin JS, Scott EP, Pui C-H, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15-20, 1994
31. Alvarez F, Berg PA, Bianchi FB, et al.: International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929-938, 1999
32. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clinica Chimica Acta 85:323-333, 1978
33. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Human Genet 32:651-662, 1980
34. Weinshilboum R: Methyltransferase pharmacogenetics. Pharmacol Ther 43:77-90, 1989
35. Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R: Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med Clin (Barc) 121:481-484, 2003
36. Czaja AJ, Carpenter HA: Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39:1631-1638, 2004
37. Czaja AJ, Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40:644-650, 2004
38. Spire-Vayron de la Moureyre C, Debuysere J, Masain B, et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125:879-887, 1998
39. McLeod HL, Pritchard SC, Githang'a J, et al.: Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence of allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9:773-776, 1999
40. Weinshilboum R: Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 29:601-605, 2001
41. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE: Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902, 1995
42. Kaskas BA, Louis E, Hindorf U, et al.: Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52:140-142, 2003
43. Sandborn WJ: Rational dosing of azathioprine and 6-mercaptopurine. Gut 48:591-592, 2001
44. Cuffari C, Theoret Y, Latour S, Seidman G: 6-mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 39:401-406, 1996
45. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705-713, 2000
46. Lowry PW, Franklin CL, Weaver AL, et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 40:665-670, 2001
47. Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C: Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 24:351-358, 2002
48. Reuter LO, Sonne J, Larsen NE, et al.: Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 38:972-979, 2003